Can ENTRESTO use pay-for-performance schemes and patient monitoring services to justify its anticipated budget impact in the U.S.?

Novartis’ recently approved ENTRESTO impressed regulators with stellar clinical outcomes, including a 20% reduction in the risk of cardiovascular death and hospitalization and a 16% improvement in overall survival compared to the standard-of-care ACE inhibitor therapy enalapril. ENTRESTO is expected to change the management of heart failure with reduced ejection…

Stepwise Expansion: Russia’s Essential Drugs List / Seven Nosologies (VZN) Programme

Russia’s Essential Drugs List (перечень жизненно необходимых и важнейших лекарственных препаратов) was created in April 2010, which enabled the federal authorities to more effectively regulate the prices of vital and essential pharmaceutical products in Russia in order to increase access to them for the public and healthcare institutions. Rosminzdrav, or…

We’re Going to Need a Bigger Boat: How UnitedHealth’s $12.8B Acquisition of Catamaran Creates a Unique Force in the Ongoing PBM Battle Against Rising Specialty Drug Costs

On March 30th, UnitedHealth Group announced it would acquire Catamaran Corporation and integrate its pharmacy services into OptumRx, UnitedHealth’s standalone pharmacy services unit. This merger is the latest in a trend that has consolidated the majority of the USA’s pharmacy benefit managers (PBMs), and gives UnitedHealth the scale to better…

Page 1 of 212